hydrazine has been researched along with Thrombopenia in 217 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (3.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (9.22) | 29.6817 |
| 2010's | 124 (57.14) | 24.3611 |
| 2020's | 66 (30.41) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA | 1 |
| Chen, Z; Cheng, X; Fu, L; Gu, H; Ma, J; Wang, X; Wu, R; Zhao, L | 1 |
| Dong, H; Hu, H; Li, Y; Liu, Q; Liu, W; Shen, Y; Wu, D; Ye, B; Zhao, Y; Zhou, Y | 1 |
| Arnold, DM; Blostein, M; Carruthers, J; Cook, RJ; Heddle, NM; Hsia, C; Jamula, E; Kassis, J; Kaur, MN; Larratt, L; Li, N; Lin, Y; Liu, Y; Sholzberg, M; Tinmouth, A; Xie, F | 1 |
| Becattini, C; Maraziti, G | 1 |
| Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M | 1 |
| Argenziano, M; Catanoso, M; Ceglie, G; Di Leva, C; Di Paola, A; Locatelli, F; Palumbo, G; Perrotta, S; Rossi, F; Tortora, C | 1 |
| Al-Samkari, H; Ayad, N; Grace, RF | 1 |
| Calvo, KR; Desmond, R; Dunbar, CE; Fan, X; Groarke, EM; Larochelle, A; Patel, B; Winkler, T; Young, DJ; Young, NS | 1 |
| Bang, SM; Kim, JH; Kim, JW; Kim, SA; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Huang, TL; Ren, P; Zhang, XW | 1 |
| Akyürek, N; Aydın Kaynar, L; Bostankolu Değirmenci, B; Dikyar, A; Özkurt, ZN; Uyar Göçün, P; Yegin, ZA | 1 |
| Kapur, R | 1 |
| Barcellini, W; Bortolotti, M; Cantoni, S; Capecchi, M; Cecchi, N; Chen, F; Fattizzo, B; Frederiksen, H; Giordano, G; Glenthøj, A; Gonzaléz-Lopez, TJ; Mingot-Castellano, ME; Napolitano, M; Patriarca, A | 1 |
| Arif, AR; Chen, W; Luo, S; Wang, Y; Xue, M; Zhao, M | 1 |
| Aksu, S; Büyükaşık, Y; Çınar, OE; Demiroğlu, H; Erdoğdu, B; Göker, H; Haznedaroğlu, İC; Karadeniz, M; Karataş, A; Malkan, ÜY; Özcebe, Oİ; Sayınalp, N; Velet, M | 1 |
| Bolster, L; Goodyear, MD; Patterson, JM; Podstawka, J; Rydz, N; Sun, HL; Wall, E | 1 |
| Li, F; Luo, S; Xu, Y; Yang, F; Zhang, X; Zong, H | 1 |
| Alrajhi, Z; Jackson, M; Kirby-Allen, M; Klaassen, RJ; Livingston, J; McGuire, C; Newhook, D | 1 |
| Al-Samkari, H | 1 |
| Cai, X; Chang, Y; Fu, H; Huang, X; Jiang, Q; Lu, J; Zhang, X; Zhao, X | 1 |
| Feng, CX; Geng, QC; Lin, X; Liu, Y; Su, J; Zhang, HX | 1 |
| Feng, X; Hua, B; Li, W; Ma, L; Wang, D; Wang, F; Wang, H; Zhu, Y | 1 |
| Fijnheer, R; Huisman, A; Koene, HR; Poolen, GC; Schutgens, REG; Thielen, N; Urbanus, RT; van Bladel, ER; van Dijk, WEM; van Galen, KPM | 1 |
| Barlassina, A; Cooper, N; González-López, TJ; Zaja, F | 1 |
| Carmi, O; Garra, W; Kivity, S; Levy, Y | 1 |
| Bátorová, A; Bodó, I; Červinek, L; Ionita, I; Lissitchkov, T; Melikyan, A; Podolak-Dawidziak, M; Pulanić, D | 1 |
| Audia, S; Azzaoui, I; Belmondo, T; Bonnotte, B; Boutin, E; Canoui-Poitrine, F; Chappert, P; Cheze, S; Comont, T; Crickx, E; Fain, O; Galicier, L; Gerfaud-Valentin, M; Gobert, D; Godeau, B; Guillet, S; Hamidou, M; Hue, S; Lambotte, O; Languille, L; Le Gallou, T; Lefrere, F; Lega, JC; Limal, N; Luka, M; Mahévas, M; Malphettes, M; Marolleau, JP; Martis, N; Menager, M; Michel, M; Morin, AS; Moulis, G; Noel, N; Perlat, A; Puyade, M; Rivière, E; Robbins, A; Roy-Peaud, F; Terriou, L; Viallard, JF; Zarrour, A | 1 |
| Borchiellini, A; Dufour, C; Farruggia, P; Giona, F; Giordano, P; Ladogana, S; Palumbo, G; Perrotta, S; Pession, A; Ramenghi, U; Russo, G; Spinelli, M; Zecca, M | 1 |
| Grosicki, S; Lawniczek, T; Mittelman, M; Platzbecker, U; Selleslag, D; Zhu, Z | 1 |
| Kulasekararaj, AG; Trikha, R | 1 |
| Bastiaanse, M; Daykin-Pont, O; Eriksson, D; Geldman, E; Gerard Jansen, AJ; McDonald, V; Morgan, M; Newland, A; Prince, S; Wilson, K; Zwaginga, JJ | 1 |
| Nikuze, L; Pang, C; Wei, H; Wu, X | 1 |
| Al-Mashdali, AF; Bakr, MM; Gulied, A; Yassin, MA | 1 |
| Chen, W; Li, L; Liu, Y; Zeng, X | 1 |
| Chang, H; Chari, A; Choquet, S; Cole, C; Comenzo, RL; Cornell, RF; Costa, LJ; Crochiere, M; Delforge, M; Dimopoulos, M; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Frenzel, L; Gavriatopoulou, M; Hoffman, JE; Huff, CA; Illmer, T; Jagannath, S; Kaminetzky, D; Karlin, L; Kauffman, MG; Landesman, Y; Levy, M; Li, L; Lonial, S; Meuleman, N; Mohty, M; Moreau, P; Nooka, AK; Parekh, S; Parker, TL; Perrot, A; Picklesimer, C; Podar, K; Raab, MS; Richardson, PG; Richter, J; Saint-Martin, JR; Schiller, G; Schreder, M; Shacham, S; Shah, J; Stewart, AK; Tang, S; Tuchman, S; Vij, R; Vlummens, P; Vogl, DT; Weisel, KC; Yee, AJ | 1 |
| Song, P; Zhang, L | 1 |
| Patel, BJ; Sekeres, MA | 1 |
| Hanna, R; Mahat, U; Rotz, SJ | 1 |
| Fagioli, F; Girardi, K; Locatelli, F; Masetti, R; Pession, A; Prete, A; Quarello, P; Vendemini, F | 1 |
| Abonour, R; Bahlis, N; Baz, R; Berdeja, JG; Chai, Y; Chari, A; Chen, C; Choquet, S; Cornell, RF; Dimopoulos, MA; Dingli, D; Gasparetto, C; Gavriatopoulou, M; Hofmeister, CC; Huff, CA; Jagannath, S; Jakubowiak, A; Kauffman, MG; Lentzsch, S; Li, K; Li, L; Lonial, S; Mohty, M; Moreau, P; Nooka, AK; Parker, TL; Reece, D; Richter, J; Shacham, S; Shah, J; Siegel, D; Tuchman, S; Unger, TJ; Vogl, DT; Weisel, KC; White, D; Yee, AJ | 1 |
| Makris, M | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| Fukuhara, S; Ito, M; Jo, H; Kanda, S; Maeshima, AM; Ohe, Y; Okuma, Y; Yoshida, T | 1 |
| Gadgeel, M; Lafferty, J; Persaud, Y; Savaşan, S; Seddiq, M | 1 |
| Fu, H; Gao, F; Huang, H; Lai, X; Luo, Y; Shi, J; Tan, Y; Yu, J; Zhao, Y; Zhou, X | 1 |
| Bury, L; Gresele, P; Paciullo, F | 1 |
| Ebbo, M; Godeau, B; Rivière, E | 1 |
| Al Nahedh, M; Alfattani, A; Alfraih, F; Alhayli, S; Alhumaid, M; Aljurf, M; Alkhudair, N; Alsaedi, H; Alseraihy, A; Alsharif, F; Alzahrani, H; Bakshi, N; Devol, E; Hanbali, A; Hashmi, SK; Rasheed, W; Samarkandi, H; Shaheen, M | 1 |
| Bussel, JB; Kuter, D | 1 |
| Abdelmoumen, K; Ballerini, P; Bordet, JC; Dargaud, Y; Ducastelle-Lepretre, S; Fabre, M; Favier, R | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kadia, T; Masarova, L; Matthews, J; Naqvi, K; Ravandi, F; Sasaki, K; Shoukier, M; Verstovsek, S | 1 |
| Fang, JP; Huang, K; Li, Y; Liao, XY; Qiu, KY; Weng, WJ; Wu, RH; Xu, HG; Xu, LH; Zhou, DH | 1 |
| Leng, Q; Wang, W; Wang, Y; Wu, L | 1 |
| Akyay, A; Öncül, Y | 1 |
| Abbinante, VM; Barreca, G; Masciocchi, N; Zampieri, M | 1 |
| Anak, S; Bayram, N; Bilgen, H; Elli, M; Nepesov, S; Özdilli, K; Şahin, Ş; Yaman, Y | 1 |
| Feng, Q; Hu, X; Li, N; Liu, A; Ma, S; Peng, J; Sheng, Z; Zhang, Y | 1 |
| Castelli, R; Gidaro, A; Lambertenghi Deliliers, G | 1 |
| Ahmed, S; Alousi, AM; Andersson, BS; Bashir, Q; Bassett, R; Champlin, R; Ciurea, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Kim, S; Konoplev, S; Nieto, Y; Olson, A; Oran, B; Parmar, S; Poon, MC; Popat, U; Qazilbash, MH; Rezvani, K; Shah, N; Shpall, EJ; Valdez, B | 1 |
| Abematsu, T; Iwamoto, J; Kawano, Y; Kodama, Y; Moriyama, M; Nakagawa, S; Nakamura, T; Nishikawa, T; Okamoto, Y | 1 |
| Balayn, N; Ballerini, P; Basso-Valentina, F; Boussard, C; Constantinescu, SN; Favier, R; Levy, G; Marty, C; Neven, B; Oufadem, M; Plo, I; Raslova, H; Vainchenker, W; Varghese, LN | 1 |
| Ceglie, G; Clemente, V; De Gennaro, F; Di Mauro, M; Nocentini, G; Palumbo, G | 1 |
| Balduini, A; Balduini, CL; Barozzi, S; Biunno, I; Bussel, JB; Di Buduo, CA; Kaplan, DL; La Spada, A; Laurent, PA; Lordier, L; Ntai, A; Pecci, A; Raslova, H; Soprano, PM; Zaninetti, C | 1 |
| Gerbitz, A; Ho, L; Kim, DDH; Kumar, R; Lam, W; Law, AD; Lipton, JH; Mattsson, J; McEwan, C; Michelis, FV; Nampoothiri, RV; Pasic, I; Thyagu, S; Viswabandya, A | 1 |
| Ades, PL; Al Jijakli, A; Azerad, MA; Berceanu, A; Beyne-Rauzy, O; Broner, J; Cherait, A; Cluzeau, T; Comont, T; Cony-Makhoul, P; Dimicoli, S; Fenaux, P; Gaudin, C; Giraud, JT; Gruson, B; Guerveno, C; Guillaume, T; Gyan, E; Jachiet, V; Laribi, K; Le Clech, L; Meunier, M; Sanhes, L; Santana, C; Slama, B; Torregrosa, J | 1 |
| Bussel, JB; Lee, EJ; Seshadri, M | 1 |
| Bubalo, J; Gilreath, J; Lo, M | 1 |
| Kurokawa, T; Ohkohchi, N | 1 |
| Crochiere, M; Italiano, JE; Kashyap, T; Klebanov, B; Landesman, Y; Liu, ZJ; Machlus, KR; Shacham, E; Sola-Visner, M; Soussou, TS; Unger, TJ; Vijey, P; Wu, SK | 1 |
| Ali, M; Ali, S; Gassas, A; Kirby-Allen, M; Krueger, J; Schechter, T | 1 |
| Balduini, A; Di Buduo, CA; Kaplan, DL | 1 |
| Gatt, A; Ng, T; Smith, M | 1 |
| De Carne, C; Elefant, E; Favier, R; Gkalea, V; Lapusneanu, R; Rigouzzo, A | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C | 1 |
| Chuai, Y; Dai, G; Nie, W; Wang, A; Zhang, X | 1 |
| Hariyama, Y; Hiraga, J; Kagami, Y; Kishigami, Y; Oguchi, H; Ohashi, H; Suzuki, N; Takagi, Y | 1 |
| Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z | 1 |
| Shastri, A; Verma, AK | 1 |
| Ai, Y; He, R; Li, X; Li, Y; Liang, Y; Xie, J; Zhang, J; Zheng, W | 1 |
| Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI | 1 |
| Balduini, CL; Pecci, A; Rodeghiero, F | 1 |
| Fu, L; Li, S; Ma, J; Qin, M; Wang, B; Wu, R; Zhang, L; Zhou, X; Zhu, G | 1 |
| Birchall, J; Doree, C; Estcourt, LJ; Hopewell, S; Malouf, R; Trivella, M | 1 |
| Arratibel, N; Avendaño, A; Baile, M; Bastida, JM; Caballero, MD; Cabrero, M; Carrillo, J; Gonzalez-Porras, JR; Lopez-Corral, L; Lopez-Parra, M; Martin, A; Perez, E; Rivera, D; Sanchez-Guijo, F; Vazquez, L; Veiga, A | 1 |
| Burger, J; Ferrajoli, A; Jain, N; Keating, M; O'Brien, S; Paul, S; Wierda, W | 1 |
| Cacace, F; Cardano, F; Frieri, C; Marano, L; Marotta, S; Pane, F; Ricci, P; Risitano, AM; Simeone, L; Trastulli, F; Vitiello, S | 1 |
| Alarcón, P; Conte, G; López, M | 1 |
| Balduini, CL; Barozzi, S; Bozzi, V; Gresele, P; Pecci, A; Zaninetti, C | 1 |
| Bastida, JM; Bento, L; Bosch-Vilaseca, A; Cabrera, R; Chinea, A; De Miguel, C; Duarte, R; Espigado, I; Fernández-Avilés, F; García-Cadenas, I; García-Torres, E; González-Porras, JR; Gutiérrez, A; Herrera, C; López, J; Martínez-Muñoz, ME; Rivera, D; Roldán, E; Sampol, A; Solano, C; Valcárcel, D; Vaz, CP; Yáñez, L; Zudaire, T | 1 |
| Frączkiewicz, J; Kazanowska, B; Sęga-Pondel, D; Ussowicz, M | 1 |
| Bakshi, KK; Brainsky, A; Tarantino, MD | 1 |
| Afdhal, NH; Giannini, EG | 1 |
| Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A | 1 |
| Aguilar, C | 1 |
| Gibiansky, E; Hayes, S; Johnson, BM; Mudd, PN; Ouellet, D; Williams, D | 1 |
| Crowther, M; Cuker, A; Siegal, D | 1 |
| Primignani, M; Tripodi, A | 1 |
| Brereton, N; Deuson, R; Hirst, A; Kutikova, L; Lee, D; Thornton, P | 1 |
| Hattori, T; Ikeda, Y; Ishii, K; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Okamoto, S; Okoshi, Y; Tomiyama, Y | 1 |
| Kuter, DJ; Makar, RS; Sahud, MA; Zhukov, OS | 1 |
| Denoyelle, F; Favier, M; Favier, R; Feriel, J; Martignetti, JA | 1 |
| Kanda, M; Kondo, M; Mukai, M; Yamamoto, S | 1 |
| Cardamone, D; Frey, NV; Glaser, L; Kricka, LJ; Milone, MC | 1 |
| Farrell, C; Hayes, SC; Wire, M; Zhang, J | 1 |
| Andolina, JR; Becker, M; Chen, Y; Constine, LS; Dawson, KL; DeBolt, J; Erickson-Miller, CL; Friedberg, J; Hyrien, O; Johnson, BM; Liesveld, JL; Milner, LA; Phillips, GL; Smudzin, T | 1 |
| Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY | 1 |
| Pathak, S; Roth, M; Steidl, U; Verma, A | 1 |
| Feld, JJ; Leber, A | 1 |
| Fujimura, K | 1 |
| Gauchan, D; Gedeon, D; Maroules, M; Shaaban, H | 1 |
| Barbosa, LS; Scheinberg, M; Scheinberg, P; Singulane, CC | 1 |
| Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T | 1 |
| Deng, H; Ji, F; Li, Z | 1 |
| Desborough, MJ; Jairath, V | 1 |
| Afdhal, NH; Theodore, D | 1 |
| Janssen, HL; Maan, R; Veldt, BJ | 1 |
| Gauchan, D; Maroules, M; Modi, Y; Shaaban, H | 1 |
| Ince, AT | 1 |
| Al-Banwan, K; Al-Jafar, HA; Al-Khaldi, J; Alduaij, A | 1 |
| Cipăian, RC; Mihăilă, RG | 1 |
| Burness, CB | 1 |
| Farrell, C; Thapar, M; Wire, MB; Zhang, J | 1 |
| Chang, H; Shih, LY | 1 |
| Abayasekara, N; Berliner, N; Jeong, JY; Laubach, J; Levine, MS; Vanasse, GJ | 1 |
| Kuter, DJ | 4 |
| Hassan, MN; Waller, EK | 1 |
| Akhtari, M; Piatek, C | 1 |
| Fujimi, A; Hashimoto, A; Hayasaka, N; Iyama, S; Kamihara, Y; Kanisawa, Y; Kato, J; Minami, S; Nakajima, C; Okuda, T; Ono, K; Yamada, S | 1 |
| Cerezuela Fuentes, P; García Coronel, M; García Lagunar, MH; Gutiérrez-Meca Maestre, DP; Martínez Ortiz, MJ; Martínez Penella, M | 1 |
| Catalá-López, F; Corrales, I; de la Fuente-Honrubia, C; González-Bermejo, D; Martín-Serrano, G; Montero, D; Saint-Gerons, DM | 1 |
| Anter, HA; Khanfar, AA; Obeidat, AR; Saleh, MI | 1 |
| Annichiarico, BE; Coretti, S; Giannini, EG; Lidonnici, D; Marchetti, M; Rodeghiero, F; Romano, F; Ruggeri, M; Sacchini, D | 1 |
| Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P | 1 |
| Barnard, MR; Berny-Lang, MA; Brigstocke, SL; Bussel, JB; Carmichael, SL; Frelinger, AL; Gerrits, AJ; Leven, EA; Michelson, AD; Mitchell, WB; Revel-Vilk, S; Tamary, H | 1 |
| Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L | 1 |
| Gounden, V; Zhao, Z | 1 |
| Naithani, R; Sachdev, M; Uttam, R | 1 |
| Kambhampati, S; Li, W; Morrone, K; Steidl, U; Verma, A; Will, B | 1 |
| de Knegt, RJ; Maan, R; Veldt, BJ | 1 |
| Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP | 1 |
| Baysal, B; Danalioglu, A; Kayar, Y; Kocaman, O; Senturk, H | 1 |
| Bührer, C; Cremer, M; Dame, C; Kling, PJ; Sallmon, H | 1 |
| Fuji, S; Fukuda, T; Inamoto, Y; Kim, SW; Kurosawa, S; Okinaka, K; Tanaka, T; Tanosaki, R; Yamashita, T | 1 |
| Aggarwal, D; Auerbach, H; Mandaliya, R | 1 |
| Chen, PJ; Giannini, EG; Grotzinger, KM; Rendas-Baum, R; Theodore, D; Younossi, ZM | 1 |
| Adams, DF; Sellers, TS | 1 |
| Alessi, MC; Fiore, M; Saut, N; Viallard, JF | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Kazemi, T; Martin, S; Worswick, S | 1 |
| Chaimani, A; Desborough, M; Doree, C; Estcourt, LJ; Hadjinicolaou, AV; Hopewell, S; Stanworth, SJ; Trivella, M; Vyas, P | 1 |
| Agard, C; Boisseau, P; Denis, CV; Espitia, O; Fouassier, M; Ternisien, C | 1 |
| Bastian, TW; Chen, MJ; Connor, JR; Duck, KA; Georgieff, MK; Lanier, LM; Liu, ZJ; Michalopoulos, GC; Sola-Visner, MC | 1 |
| Ahmed, KN; Hafeez, M; Khan, RG; Rafe, A; Rasool, G; Sarfraz, T | 1 |
| Alati, C; Avanzini, P; Balleari, E; Bocchia, M; Bova, I; Buccisano, F; Carluccio, P; Cortelezzi, A; Cufari, P; D'Errigo, MG; Fenaux, P; Germing, U; Impera, S; Kulasekararaj, A; Latagliata, R; Liberati, AM; Mancini, S; Molteni, A; Morabito, F; Niscola, P; Oliva, EN; Palumbo, GA; Poloni, A; Salutari, P; Salvi, F; Sanpaolo, G; Santacaterina, I; Santini, V; Spiriti, MA; Stamatoullas, A; Voso, MT; Zini, G | 1 |
| Laskou, F; McGuckin, S; Scully, M; Taylor, A; Westwood, JP | 1 |
| Giannini, EG; Savarino, V | 1 |
| Arnason, JE; Bussel, JB; Levy, B | 1 |
| Godeau, B | 1 |
| McHutchison, JG; Patel, K; Tillmann, HL | 1 |
| Panzer, S | 1 |
| Newland, A | 1 |
| Dusheiko, G | 1 |
| Abboud, M; Aivado, M; Erhardt, JA; Erickson-Miller, CL; Pillarisetti, K; Toomey, JR | 1 |
| Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B | 1 |
| Miyakawa, Y | 1 |
| Leitch, HA; Vickars, LM | 1 |
| Chitlur, M; Nugent, DJ; Roganovic, J; Tamary, H | 1 |
| Imbach, P; Kühne, T | 1 |
| Bowen, C; Jenkins, J; Matthys, G; McGuire, S; Park, JW; Peng, B; Williams, D; Wire, MB | 1 |
| Corman, SL; Mohammad, RA | 1 |
| Cenci, T; Foà, R; Giona, F; Larocca, LM; Leone, G; Martini, M; Teofili, L; Torti, L | 1 |
| Bussel, JB; Kuter, DJ | 1 |
| Balduini, CL; Bozzi, V; Fierro, T; Gresele, P; Klersy, C; Melazzini, F; Mezzasoma, AM; Noris, P; Pecci, A; Savoia, A | 1 |
| Bussel, JB; Pinheiro, MP | 1 |
| Rhodes, E; Stasi, R | 1 |
| Salama, A | 1 |
| Brainsky, A; Grotzinger, KM; Signorovitch, J | 1 |
| Ay, C; Haselboeck, J; Koder, S; Pabinger, I; Panzer, S | 1 |
| Cheng, G | 1 |
| Duic, JP; Grewal, J; Haas, J; Kesari, S; McConie, K; Staszewski, H | 1 |
| Crowther, M; Imbach, P | 1 |
| Jansen, AJ; Swart, RM; te Boekhorst, PA | 1 |
| Frederiksen, H; Gudbrandsdottir, S; Hasselbalch, H | 1 |
| Calvo, G; Catalá-López, F; Corrales, I; Martín-Serrano, G; Tobías, A | 1 |
| Balduini, CL; Barozzi, S; d'Amico, S; Pecci, A | 1 |
| Becker, M; Bennett, JM; Chen, Y; Liesveld, J; Milner, L; Phillips, GL; Reid, R | 1 |
| Fujiyama, S; Hattori, T; Katsura, K; Kawaguchi, T; Komori, A; Nakamuta, M; Oketani, M; Sakisaka, S; Sasaki, Y; Sata, M; Seike, M; Tanaka, M; Watanabe, H | 1 |
| Brümmendorf, TH; Ehninger, G; Jakob, C; Platzbecker, U; Schleyer, E; Siegert, G; Trautmann, K; von Grünhagen, U | 1 |
| Basciano, PA; Bussel, JB | 1 |
| Afdhal, NH; Andriulli, A; Brainsky, A; Campbell, F; Chen, PJ; Giannini, EG; Han, KH; Hyde, D; Jeffers, L; Lee, JW; McHutchison, J; Mohsin, A; Tayyab, G; Theodore, D | 1 |
| Korman, T; Lee, LY; Quach, H; Smith, B; Woolley, IJ | 1 |
| Aiba, K; Furukawa, K; Futagawa, Y; Ito, R; Misawa, T; Uwagawa, T; Yahagi, Y; Yanaga, K | 1 |
| Lisman, T; Porte, RJ | 1 |
| Pignatelli, P; Violi, F | 1 |
| Catani, L; Iacobucci, I; Martinelli, G; Palandri, F; Polverelli, N; Vianelli, N | 1 |
| Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G | 1 |
| Chumsri, S; Zimrin, A | 1 |
| BRUNNER, KW; YOUNG, CW | 1 |
| Andreeff, M; Beran, M; Cahill, A; Clairmont, C; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, H; Koller, C; Sznol, M; Thomas, D; Verstovsek, S | 1 |
| Chu, E; Clairmont, C; Egorin, M; Kummar, S; Modiano, M; Murren, J; Sznol, M | 1 |
| Collins, D; Deng, Y; Erickson-Miller, CL; Jenkins, JM; Kitchen, V; Uhl, J; Williams, D | 1 |
| Afdhal, NH; Berg, T; Blackman, N; Bourliere, M; Campbell, FM; Dusheiko, G; Gordon, SC; Jenkins, J; McHutchison, JG; Rodriguez-Torres, M; Shiffman, ML; Sigal, S; Theodore, D | 1 |
| Schwartz, RS | 1 |
| Lawson, A | 1 |
| Bussel, JB; Kobos, R | 1 |
| Bernard, J; Blom, J; Boiron, M; Brunner, K; Cooper, MR; Cuttner, J; Ellison, RR; Gailani, S; Glidewell, OJ; Haurani, F; Holland, JF; Hoogstraten, B; Jacquillat, C; Levy, R; Lowenstein, L; Nissen, NI; Rege, VB; Serpick, AA; Silver, RT; Wasserman, L; Weil, M; Wiernik, PH | 1 |
| Clément, F | 1 |
| Hansen, MM; Hertz, H; Videaek, A | 1 |
| Hjelt, AL; Holsti, LR | 1 |
| Martin, H; Schubert, JC | 1 |
| Ikkala, E; Penttilä, O | 1 |
52 review(s) available for hydrazine and Thrombopenia
| Article | Year |
|---|---|
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Topics: Benzoates; Child; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.
Topics: Antineoplastic Agents; Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
Topics: Adult; Benzoates; Humans; Hydrazines; Incidence; Network Meta-Analysis; Purpura, Thrombocytopenic, Idiopathic; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review.
Topics: Benzoates; Connective Tissue Diseases; Humans; Hydrazines; Immunosuppressive Agents; Leukopenia; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Treatment Outcome | 2023 |
European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Topics: Adult; Benzoates; Consensus; COVID-19; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis.
Topics: Antineoplastic Agents; Benzoates; Hemorrhage; Humans; Hydrazines; Neoplasms; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2023 |
Lowering the boom on lower-risk myelodysplastic syndromes.
Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia | 2019 |
Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Platelet Count; Platelet Transfusion; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2020 |
[Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later].
Topics: Adult; Autoimmunity; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Thrombosis | 2021 |
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Topics: Benzoates; Cinnamates; Dose-Response Relationship, Drug; Drug Monitoring; Health Knowledge, Attitudes, Practice; Humans; Hydrazines; Pharmacists; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2021 |
Platelets in liver disease, cancer and regeneration.
Topics: Animals; Benzoates; Blood Platelets; Cell Movement; Clinical Trials as Topic; End Stage Liver Disease; Fibrosis; Hepatic Stellate Cells; Humans; Hydrazines; Killer Cells, Natural; Liver; Liver Diseases; Liver Regeneration; Neoplasm Metastasis; Neoplasms; Pyrazoles; Regeneration; Shear Strength; Thrombocytopenia; Thrombopoietin | 2017 |
In vitro generation of platelets: Where do we stand?
Topics: Animals; Benzoates; Bioreactors; Blood Platelets; Bone Marrow; Cell Culture Techniques; Cells, Cultured; Cellular Microenvironment; Health Services Needs and Demand; Humans; Hydrazines; Megakaryocytes; Models, Animal; Platelet Transfusion; Pyrazoles; Thrombocytopenia; Thrombopoiesis | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Humans; Hydrazines; Middle Aged; Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2017 |
Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Infant; Male; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2018 |
Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Topics: Benzoates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Association Studies; Genetic Heterogeneity; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Hydrazines; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Thrombocytopenia; Thrombophilia; Thrombopoiesis; Thrombopoietin | 2018 |
Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
Topics: Adult; Benzoates; Deamino Arginine Vasopressin; Hemostatics; Humans; Hydrazines; Plasma; Platelet Transfusion; Postoperative Care; Postoperative Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2018 |
Eltrombopag in patients with chronic liver disease.
Topics: Animals; Benzoates; Chronic Disease; Hematologic Agents; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2013 |
Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Topics: Benzoates; Blood Platelets; Chronic Disease; Drug Dosage Calculations; Hemophilia A; Hemorrhage; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia; Thrombopoietin | 2013 |
Thrombopoietin receptor agonists in primary immune thrombocytopenia.
Topics: Benzoates; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2013 |
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
[Pathogenesis and management of immune thrombocytopenia].
Topics: Adrenocorticotropic Hormone; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Blood Platelets; Dexamethasone; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Rituximab; Splenectomy; Thrombocytopenia | 2014 |
Eltrombopag in chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Blood Platelets; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Signal Transduction; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2014 |
Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.
Topics: Benzoates; Hepatitis C, Chronic; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2014 |
Managing thrombocytopenia associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Benzoates; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Evidence-Based Medicine; Gemcitabine; Humans; Hydrazines; Neoplasms; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2015 |
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Benzoates; Hematologic Agents; Humans; Hydrazines; Models, Statistical; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thromboembolism; Thrombopoietin | 2015 |
Eltrombopag for treatment of thrombocytopenia-associated disorders.
Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis | 2015 |
Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Topics: Antineoplastic Agents; Benzoates; Blood Platelets; Cell Differentiation; Gene Expression Regulation, Neoplastic; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Myelodysplastic Syndromes; Platelet Transfusion; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin | 2016 |
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Topics: Benzoates; Chronic Disease; Disease Management; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2015 |
Thrombocytopenia and platelet transfusion in the neonate.
Topics: Benzoates; Clinical Decision-Making; Hematologic Agents; Humans; Hydrazines; Infant, Newborn; Intensive Care, Neonatal; Platelet Transfusion; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2016 |
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Topics: Benzoates; Bone Marrow Diseases; Chronic Disease; Deamino Arginine Vasopressin; Hemorrhage; Hemostatics; Humans; Hydrazines; Platelet Transfusion; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Tranexamic Acid | 2016 |
Thrombocytopenia in liver disease.
Topics: Benzoates; Embolization, Therapeutic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Splenectomy; Thrombocytopenia | 2008 |
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Topics: Benzoates; Blood Platelets; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Hemorrhage; Hepatitis C; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2008 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Hepacivirus; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2009 |
Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C.
Topics: Benzoates; Bone Marrow; Carrier Proteins; Hematologic Agents; Hepatitis C; Humans; Hydrazines; Liver Cirrhosis; Liver Diseases; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
New thrombopoietic growth factors.
Topics: Benzoates; Clinical Trials as Topic; Hematology; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Models, Biological; Models, Chemical; Peptides; Platelet Count; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Time Factors; Treatment Outcome | 2009 |
[Development of thrombopoietin receptor agonists].
Topics: Animals; Benzoates; Clinical Trials as Topic; Drug Discovery; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin | 2009 |
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Hematopoietic Cell Growth Factors; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Off-Label Use; Phlebotomy; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoietin | 2010 |
Eltrombopag: a novel oral thrombopoietin receptor agonist.
Topics: Administration, Oral; Animals; Benzoates; Humans; Hydrazines; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2010 |
Eltrombopag.
Topics: Animals; Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Mice; Neoplasms; Pyrazoles; Thrombocytopenia | 2011 |
Current status of thrombopoietic agents.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2010 |
Current treatment options for primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Azathioprine; Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Isoantibodies; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rho(D) Immune Globulin; Rituximab; Thrombocytopenia; Thrombopoietin | 2011 |
Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Topics: Adult; Autoimmune Diseases; Benzoates; Female; Humans; Hydrazines; Platelet Count; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2011 |
What is the potential for thrombopoietic agents in acute leukemia?
Topics: Adult; Benzoates; Blood Platelets; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Hydrazines; Leukemia, Myeloid, Acute; Molecular Mimicry; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Remission Induction; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Time Factors | 2011 |
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Benzoates; Hematologic Agents; Humans; Hydrazines; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia; Thromboembolism; Thrombopoietin | 2012 |
Thrombopoietin-receptor agonists.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2012 |
Overview of thrombopoietic agents in the treatment of thrombocytopenia.
Topics: Animals; Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recombinant Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2008 |
33 trial(s) available for hydrazine and Thrombopenia
| Article | Year |
|---|---|
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Hydrazines; Lung Neoplasms; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Triazoles; Vomiting | 2022 |
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Intention to Treat Analysis; Karyopherins; Male; Middle Aged; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Analysis; Thrombocytopenia; Triazoles; Young Adult | 2019 |
Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Topics: Adolescent; Adult; Allografts; Benzoates; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Infant; Male; Pyrazoles; Thrombocytopenia | 2020 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Benzoates; Humans; Hydrazines; Neoplasm Recurrence, Local; Pyrazoles; Thrombocytopenia | 2021 |
CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag.
Topics: Adult; Amino Acid Substitution; Benzoates; Calreticulin; Child; Child, Preschool; Congenital Bone Marrow Failure Syndromes; Female; HEK293 Cells; Homozygote; Humans; Hydrazines; Infant; Male; Mutation, Missense; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2021 |
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Topics: Animals; Apoptosis; Blood Platelets; Bone Marrow; Cell Count; Cell Differentiation; Dose-Response Relationship, Drug; Fetus; Hydrazines; Liver; Megakaryocytes; Mice, Knockout; Platelet Activation; Signal Transduction; Stem Cells; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Triazoles | 2017 |
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Topics: Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Placebos; Pyrazoles; Safety; Thrombocytopenia | 2018 |
Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Topics: Antiviral Agents; Bayes Theorem; Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Pyrazoles; Thrombocytopenia | 2019 |
Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Topics: Adult; Aged; Allografts; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2019 |
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrazoles; Thrombocytopenia | 2019 |
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Topics: Adolescent; Adult; Allografts; Benzoates; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Infant; Male; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index; Spain; Thrombocytopenia; Thrombopoietin | 2019 |
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Hydrazines; Ifosfamide; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia; Young Adult | 2013 |
Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Topics: Administration, Oral; Adult; Aged; Asian People; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Topics: Adult; Aged; Benzoates; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Stem Cell Transplantation; Thrombocytopenia; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2013 |
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2014 |
Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2015 |
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
Topics: Adolescent; Adult; Benzoates; Case-Control Studies; Child; Child, Preschool; Genetic Diseases, X-Linked; Humans; Hydrazines; Infant; Male; Mean Platelet Volume; P-Selectin; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Wiskott-Aldrich Syndrome; Young Adult | 2015 |
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Double-Blind Method; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2015 |
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Topics: Aged; Aged, 80 and over; Benzoates; Disease Progression; Female; Humans; Hydrazines; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Single-Blind Method; Thrombocytopenia; Treatment Outcome | 2017 |
Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Topics: Adult; Area Under Curve; Benzoates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hematologic Agents; Humans; Hydrazines; Male; Middle Aged; Platelet Aggregation; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Thrombocytopenia; Thrombopoiesis; Time Factors; Young Adult | 2011 |
Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; Dose-Response Relationship, Drug; Female; Genetic Predisposition to Disease; Humans; Hydrazines; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Platelet Aggregation; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Survival Rate; Thrombocytopenia; Treatment Outcome; Young Adult | 2010 |
Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Fatigue; Female; Hemorrhage; Humans; Hydrazines; Male; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Sickness Impact Profile; Thrombocytopenia; Time | 2011 |
Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Blood Platelets; Cell Aggregation; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Monocytes; P-Selectin; Placebos; Platelet Activation; Platelet Aggregation; Pyrazoles; Thrombocytopenia | 2012 |
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2012 |
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Double-Blind Method; Elective Surgical Procedures; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Young Adult | 2012 |
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Area Under Curve; Humans; Hydrazines; Leukemia, Myeloid; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Sulfonamides; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hydrazines; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Sulfonamides; Thrombocytopenia | 2005 |
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Topics: Administration, Oral; Adult; Benzoates; Blood Platelets; Dose-Response Relationship, Drug; Humans; Hydrazines; Male; Placebos; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis; Time Factors | 2007 |
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Double-Blind Method; Female; Headache; Hepatitis C; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Thrombopoietin; Recombinant Proteins; Thrombocytopenia | 2007 |
[Cytostatic treatment of lymphogranulomatosis. Experiences with ibenzmethyzine, cyclophosphamide and vinblastine sulfate].
Topics: Alopecia; Ambulatory Care; Antineoplastic Agents; Cyclophosphamide; Hodgkin Disease; Humans; Hydrazines; Injections, Intravenous; Leukopenia; Nausea; Sulfates; Thrombocytopenia; Thrombophlebitis; Vinblastine; Vomiting | 1968 |
132 other study(ies) available for hydrazine and Thrombopenia
| Article | Year |
|---|---|
Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.
Topics: Benzoates; Child; Child, Preschool; China; Humans; Hydrazines; Longitudinal Studies; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Efficiency and safety of eltrombopag for multi-line failed Chinese patients with immune thrombocytopenia: cases with decreased megakaryocyte response well from single-center experience.
Topics: Benzoates; China; Humans; Hydrazines; Megakaryocytes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.
Topics: Benzoates; Canada; Cost-Benefit Analysis; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2022 |
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia.
Topics: Antibodies; Benzoates; COVID-19; COVID-19 Vaccines; Female; Humans; Hydrazines; Middle Aged; Platelet Factor 4; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Thrombosis; Vaccines | 2022 |
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia | 2022 |
Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.
Topics: Anti-Inflammatory Agents; Benzoates; Child; Humans; Hydrazines; Iron; Mesenchymal Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2022 |
Long-term eltrombopag for bone marrow failure depletes iron.
Topics: Anemia, Aplastic; Benzoates; Ferritins; Humans; Hydrazines; Iron; Iron Overload; Pancytopenia; Pyrazoles; Recurrence; Thrombocytopenia | 2022 |
Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Topics: Adult; Benzoates; Child, Preschool; Female; Humans; Hydrazines; Infant; Infant, Newborn; Male; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Splenectomy; Thrombocytopenia; Thrombopoietin | 2022 |
Treatment of Severe Refractory Thrombocytopenia in Brucellosis with Eltrombopag: A Case Report.
Topics: Benzoates; Brucellosis; Child, Preschool; Female; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2022 |
Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia.
Topics: Benzoates; Female; Fibrosis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Primary Myelofibrosis; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory; Thrombocytopenia; Thrombopoietin | 2022 |
Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
Topics: Benzoates; Hearing Loss, Sensorineural; Humans; Hydrazines; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Pyrazoles; Thiazoles; Thiophenes; Thrombocytopenia; Treatment Failure | 2022 |
Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation.
Topics: Benzoates; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Topics: Adult; Canada; Chronic Disease; Hemorrhage; Humans; Hydrazines; Intracranial Hemorrhages; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Interleukin-4; Macrophages; Monocytes; Phenotype; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi-structured interviews.
Topics: Child; Hematologic Agents; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombocytopenia; Thrombopoietin | 2023 |
Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
Topics: Adult; Benzoates; Drug Substitution; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
Topics: Adult; Factor VIII; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Thrombin; Thrombocytopenia; Thrombophilia; von Willebrand Factor | 2023 |
Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.
Topics: Adult; Autoimmunity; Humans; Hydrazines; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Topics: Adult; Benzoates; Child; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukopenia; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2023 |
Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Myelodysplastic Syndromes; Thrombocytopenia | 2023 |
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Netherlands; Patient Preference; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Young Adult | 2023 |
Analysis of clinical characteristics and treatment efficacy in two pediatric cases of
Topics: Benzoates; Humans; Hydrazines; Infant; Intercellular Signaling Peptides and Proteins; Mutation; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Treatment Outcome | 2023 |
Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar.
Topics: Benzoates; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Qatar; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Benzoates; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Humans; Hydrazines; Lung Neoplasms; Male; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2019 |
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Topics: Aged; Antineoplastic Agents; Appetite; Clinical Trials as Topic; Diarrhea; Fatigue; Female; Humans; Hydrazines; Hyponatremia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia; Triazoles | 2020 |
Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2020 |
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Benzoates; Carcinoma, Non-Small-Cell Lung; Humans; Hydrazines; Lung Neoplasms; Pyrazoles; Thrombocytopenia | 2020 |
Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim.
Topics: Benzoates; Blood Platelets; Bone Marrow; Combined Modality Therapy; Consanguinity; Drug Substitution; Ecchymosis; Exome Sequencing; Female; Humans; Hydrazines; Immunophenotyping; Infant; Platelet Transfusion; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Tetraspanin 29; Thrombocytopenia; Thrombopoietin | 2020 |
Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.
Topics: Adolescent; Adult; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Retrospective Studies; Risk Factors; Thrombocytopenia | 2020 |
Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Blood Loss, Surgical; Endoscopy, Digestive System; Female; Humans; Hydrazines; Myosin Heavy Chains; Pancreatic Neoplasms; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2020 |
Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation: Rertrospective Observational Trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Retrospective Studies; Thrombocytopenia | 2022 |
Preparing patients with immune thrombocytopenia for surgery: what are the options?
Topics: Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2020 |
Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia.
Topics: Adult; Benzoates; Blood Cell Count; Blood Platelets; Core Binding Factor Alpha 2 Subunit; ETS Translocation Variant 6 Protein; Female; Heterozygote; Humans; Hydrazines; Pedigree; Proto-Oncogene Proteins c-ets; Pyrazoles; Repressor Proteins; Severity of Illness Index; Thrombocytopenia | 2021 |
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Eltrombopag as first-line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation.
Topics: Benzoates; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2021 |
Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Thrombocytopenia; Thrombopoietin | 2021 |
Comment on: Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Topics: Benzoates; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2020 |
Preparation and Solid-State Characterization of Eltrombopag Crystal Phases.
Topics: Benzoates; Crystallization; Crystallography, X-Ray; Humans; Hydrazines; Hydrogen Bonding; Molecular Structure; Powder Diffraction; Pyrazoles; Solvents; Thermogravimetry; Thrombocytopenia; Water; X-Ray Diffraction | 2020 |
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Female; Follow-Up Studies; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2021 |
Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron.
Topics: Adult; Animals; Antiviral Agents; Benzoates; Cell Survival; Cells, Cultured; Female; Hepatitis B, Chronic; Humans; Hydrazines; Interferon-alpha; Iron; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; THP-1 Cells; Thrombocytopenia | 2021 |
Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
Topics: Aged; Benzoates; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2021 |
[Improvement in platelet count and bleeding symptom during treatment with eltrombopag in a patient with X-linked thrombocytopenia].
Topics: Adolescent; Benzoates; Genetic Diseases, X-Linked; Humans; Hydrazines; Male; Platelet Count; Pyrazoles; Thrombocytopenia | 2021 |
Immune thrombocytopenia in two infant cases managed with eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Infant; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Topics: Adult; Aged; Benzoates; Bioreactors; Blood Platelets; Cell Culture Techniques; Cells, Cultured; Female; Fibroins; Hematopoietic Stem Cells; Humans; Hydrazines; Induced Pluripotent Stem Cells; Intercellular Signaling Peptides and Proteins; Male; Megakaryocytes; Middle Aged; Miniaturization; Mutation; Myosin Heavy Chains; Pyrazoles; Receptors, Thrombopoietin; Stem Cell Niche; Thrombocytopenia; Thrombopoiesis; Young Adult | 2021 |
Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation.
Topics: Benzoates; Costs and Cost Analysis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2021 |
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Topics: Aged; Aged, 80 and over; Benzoates; Blood Platelets; Female; France; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia | 2021 |
Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2021 |
Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
Topics: Benzoates; Child; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Thrombocytopenia | 2017 |
Primary immune thrombocytopenia in adults: clinical practice versus management guidelines.
Topics: Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Benzoates; Humans; Hydrazines; Immunoglobulins; Immunologic Factors; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombocytopenia; Thrombopoietin | 2017 |
Eltrombopag to Treat Thrombocytopenia During Last Month of Pregnancy in a Woman With MYH9-Related Disease: A Case Report.
Topics: Adult; Benzoates; Female; Hearing Loss, Sensorineural; Humans; Hydrazines; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2018 |
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2017 |
A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
Topics: Adult; Benzoates; Cesarean Section; Female; Humans; Hydrazines; Infant, Low Birth Weight; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2018 |
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk; Thrombocytopenia | 2018 |
Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Gaucher Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Platelet Count; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Thrombocytopenia; Thrombopoietin | 2019 |
Eltrombopag for post-transplant cytopenias due to poor graft function.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2019 |
[Hereditary thrombocytopenia associated with a mutation in the MYH-9 gene. Report of one case].
Topics: Benzoates; Biopsy; Female; Genetic Diseases, Inborn; Hearing Loss, Sensorineural; Humans; Hydrazines; Middle Aged; Mutation; Platelet Count; Pyrazoles; Thrombocytopenia | 2018 |
Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia.
Topics: Benzoates; Blood Loss, Surgical; Female; Humans; Hydrazines; Male; Myosin Heavy Chains; Postoperative Hemorrhage; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2019 |
Eltrombopag Therapy in Children With Rare Disorders Associated With Thrombocytopenia.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Benzoates; Child; Child, Preschool; Congenital Bone Marrow Failure Syndromes; DiGeorge Syndrome; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Lipid Metabolism, Inborn Errors; Male; Mitochondrial Diseases; Muscular Diseases; Prognosis; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Wiskott-Aldrich Syndrome | 2020 |
Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
Topics: Adult; Aged; Benzoates; Blood Loss, Surgical; Blood Platelets; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Postoperative Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Procedures, Operative; Thrombocytopenia | 2014 |
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Neoplasms; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome; Young Adult | 2013 |
Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia.
Topics: Benzoates; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Hemorrhage; Humans; Hydrazines; Immunoglobulins, Intravenous; Ireland; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombocytopenia; Thrombopoietin | 2013 |
Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Topics: Adult; Aged; Antiphospholipid Syndrome; Benzoates; Bone Marrow Diseases; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydrazines; Male; Middle Aged; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2013 |
First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
Topics: Adolescent; Benzoates; Chromosome Aberrations; Female; Humans; Hydrazines; Molecular Motor Proteins; Mutation, Missense; Myosin Heavy Chains; Otitis Media; Platelet Count; Preoperative Care; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Tympanic Membrane Perforation; Tympanoplasty | 2013 |
[Case report; a thromboembolic event in a patient with antiphospholipid antibody associated thrombocytopenia during eltrombopag therapy].
Topics: Aged; Antibodies, Antiphospholipid; Benzoates; Female; Heparin; Humans; Hydrazines; Pyrazoles; Thrombocytopenia; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Eltrombopag and serum of a different hue.
Topics: Aged; Aged, 80 and over; Benzoates; Bilirubin; Humans; Hydrazines; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Pigmentation; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Blood Platelets; Chronic Disease; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Female; Healthy Volunteers; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Platelet Count; Pyrazoles; Randomized Controlled Trials as Topic; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Does eltrombopag really ENABLE SVR?
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
Topics: Aged, 80 and over; Benzoates; Bone Marrow; Erythrocyte Transfusion; Female; Hemorrhagic Disorders; Humans; Hydrazines; Myelodysplastic Syndromes; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2014 |
Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2014 |
Eltrombopag for thrombocytopenic patients with hepatitis C virus infection and cirrhosis.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Is treatment of moderate thrombocytopenia indicated for patients with HCV infection and cirrhosis?
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Reply: To PMID 24126097.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Eltrombopag for thrombocytopenic patients with chronic HCV infection.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2015 |
Do we have to worry for thrombocytopenia during treatment of hepatitis C.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.
Topics: Benzoates; Female; Hepatitis C; Humans; Hydrazines; Middle Aged; Off-Label Use; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2014 |
Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Blood Platelets; Case-Control Studies; Computer Simulation; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Platelet Count; Polyethylene Glycols; Polypharmacy; Pyrazoles; Recombinant Proteins; Thrombocytopenia; Thrombopoiesis; Young Adult | 2015 |
Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal, Murine-Derived; Benzoates; Hemorrhage; Humans; Hydrazines; Immunoglobulins; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Male; Platelet Count; Platelet Transfusion; Pyrazoles; Rituximab; Thrombocytopenia | 2015 |
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Topics: Benzoates; Cell Line, Tumor; Hematopoiesis; Humans; Hydrazines; In Vitro Techniques; Megakaryocytes; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2015 |
Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2015 |
Thrombocytopenia: optimizing approaches in cancer patients.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2015 |
Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
Topics: Allografts; Autoantibodies; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Lymphoma, Follicular; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2015 |
[Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors].
Topics: Aged; Antineoplastic Agents; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Off-Label Use; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2015 |
Economic assessment of eltrombopag in the treatment of thrombocytopenia.
Topics: Antiviral Agents; Benzoates; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Hydrazines; Markov Chains; Pyrazoles; Quality-Adjusted Life Years; Thrombocytopenia | 2015 |
Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Topics: Antiviral Agents; Benzoates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepatitis C; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2015 |
Eltrombopag interference in routine chemistry testing.
Topics: Anemia, Aplastic; Artifacts; Benzoates; Blood Chemical Analysis; Cholesterol; Female; Humans; Hydrazines; Middle Aged; Phosphates; Pyrazoles; Thrombocytopenia; Triglycerides | 2016 |
Successful Use of Eltrombopag in a Child With Hurler Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Benzoates; Child, Preschool; Cytomegalovirus Infections; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Mucopolysaccharidosis I; Pyrazoles; Sepsis; Stenotrophomonas maltophilia; Thrombocytopenia | 2016 |
Eltrombopag: How secure in triple therapy of HCV?
Topics: Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Middle Aged; Pyrazoles; Thrombocytopenia | 2015 |
Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Allografts; Benzoates; Blood Platelets; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Megakaryocytes; Middle Aged; Platelet Count; Pyrazoles; Recovery of Function; Retrospective Studies; Thrombocytopenia | 2016 |
A Challenging Case of Splenomegaly and Refractory Thrombocytopenia.
Topics: Benzoates; Biomarkers, Tumor; Biopsy; Hemangiosarcoma; Humans; Hydrazines; Immunohistochemistry; Male; Middle Aged; Pyrazoles; Splenectomy; Splenic Neoplasms; Splenomegaly; Thrombocytopenia; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrazoles; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; United States | 2016 |
Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method.
Topics: Adult; Azo Compounds; Benzoates; Bilirubin; Color; Coloring Agents; Diagnosis, Differential; Hematinics; Humans; Hydrazines; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Osmolar Concentration; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Serum; Spectrophotometry; Thrombocytopenia | 2016 |
Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia.
Topics: Aged; Benzoates; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Male; Mutation; Nuclear Proteins; Preoperative Care; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2016 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Topics: Adult; Anemia, Aplastic; Back; Benzoates; Drug Eruptions; Humans; Hydrazines; Male; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2016 |
Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
Topics: Amino Acid Substitution; Benzoates; Female; Humans; Hydrazines; Intracranial Hemorrhages; Middle Aged; Mutation, Missense; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; von Willebrand Disease, Type 2; von Willebrand Factor | 2017 |
Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development.
Topics: Anemia, Iron-Deficiency; Animals; Benzoates; Biological Transport; Biomimetics; Blood-Brain Barrier; Cattle; Chelating Agents; Deferoxamine; Dendrites; Green Fluorescent Proteins; Hippocampus; Hydrazines; Iron; Mice; Microcirculation; Neuroglia; Neurons; Pyrazoles; Thrombocytopenia; Thrombopoietin | 2017 |
Hepatitis B Leading to Megaloblastic Anemia and Catastrophic Peripheral Thrombocytopenia.
Topics: Adult; Anemia, Megaloblastic; Benzoates; Folic Acid; Folic Acid Deficiency; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Hydrazines; Male; Platelet Count; Polymerase Chain Reaction; Pyrazoles; Tenofovir; Thrombocytopenia; Vitamin B 12; Vitamin B 12 Deficiency; Vitamin B Complex | 2016 |
Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2017 |
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors | 2009 |
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2009 |
Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Topics: Benzoates; Blood Platelets; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Hydrazines; Male; P-Selectin; Platelet Aggregation; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; STAT Transcription Factors; Thrombocytopenia; Thrombopoietin | 2009 |
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Animals; Apoptosis; Benzoates; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Megakaryocytes; Mice; Mice, Inbred NOD; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Xenograft Model Antitumor Assays | 2009 |
Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Benzoates; Child; Hemorrhage; Humans; Hydrazines; Immunologic Factors; Precision Medicine; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Severity of Illness Index; Splenectomy; Switzerland; Thrombocytopenia; Thrombopoietin | 2010 |
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Topics: Benzoates; Humans; Hydrazines; Mutation; Primary Myelofibrosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombocytosis; Thrombopoietin; Transcriptional Activation | 2010 |
New thrombopoietic agents: introduction.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Thrombocytopenia; Thrombopoietin | 2010 |
Eltrombopag for the treatment of immune thrombocytopenia.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2011 |
Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient.
Topics: Aged; Benzoates; Central Nervous System Neoplasms; Glioblastoma; Humans; Hydrazines; Male; Pyrazoles; Radiotherapy; Thrombocytopenia | 2012 |
Thrombopoietin-receptor agonists for immune thrombocytopenia.
Topics: Autoimmune Diseases; Benzoates; Female; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2011 |
Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Benzoates; Blood Platelets; Celiac Disease; Denmark; Female; HIV Infections; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Male; Middle Aged; Off-Label Use; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Retrospective Studies; Thrombocytopenia; Thrombopoietin | 2012 |
Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.
Topics: Adult; Benzoates; Bleeding Time; Blood Loss, Surgical; Coagulants; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Heredity; Humans; Hydrazines; Molecular Motor Proteins; Mutation, Missense; Myosin Heavy Chains; Orthopedic Procedures; Phenotype; Postoperative Hemorrhage; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Topics: Adult; Benzoates; Fatal Outcome; Female; Humans; Hydrazines; Middle Aged; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2012 |
Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Diamond-Blackfan; Benzoates; Cardiology; Dyskeratosis Congenita; Female; Humans; Hydrazines; Male; Megakaryocytes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2012 |
Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia.
Topics: Adenine; Benzoates; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Seropositivity; Humans; Hydrazines; Immune Reconstitution Inflammatory Syndrome; Male; Middle Aged; Organophosphonates; Oxazines; Pyrazoles; Reverse Transcriptase Inhibitors; Thrombocytopenia; Treatment Outcome | 2012 |
Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
Topics: Adult; Benzoates; Chronic Disease; Dexamethasone; Female; Glucocorticoids; Humans; Hydrazines; Prednisolone; Pyrazoles; Receptors, Thrombopoietin; Splenectomy; Thrombocytopenia | 2013 |
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Topics: Benzoates; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2012 |
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Topics: Benzoates; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2012 |
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Topics: Adult; Aged; Autoimmune Diseases; Benzoates; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydrazines; Polymorphism, Single Nucleotide; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2013 |
Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab.
Topics: Acute Disease; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Benzoates; Drug Combinations; Female; Humans; Hydrazines; Hydrocortisone; Immunoglobulins, Intravenous; Middle Aged; Prednisone; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2013 |
Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Resistance; Female; Humans; Hydrazines; Mastectomy, Segmental; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Estrogen; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Splenectomy; Taxoids; Thrombocytopenia; Thrombopoietin | 2013 |
A METHYLHYDRAZINE DERIVATIVE IN HODGKIN'S DISEASE AND OTHER MALIGNANT NEOPLASMS. THERAPEUTIC AND TOXIC EFFECTS STUDIED IN 51 PATIENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow; Brain; Drug Therapy; Hodgkin Disease; Hydrazines; Leukopenia; Liver; Lung; Methylhydrazines; Neoplasms; Pathology; Pharmacology; Radiography, Thoracic; Thrombocytopenia; Toxicology; Vinblastine | 1965 |
Immune thrombocytopenic purpura--from agony to agonist.
Topics: Benzoates; Hepatitis C; History, 20th Century; Humans; Hydrazines; Liver Cirrhosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2007 |
Eltrombopag in thrombocytopenia.
Topics: Benzoates; Hepatitis C; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Thrombopoietin; Recombinant Proteins; Thrombocytopenia | 2008 |
Daunorubicin in the therapy of acute granulocytic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Platelets; Blood Transfusion; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Hyperplasia; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Thrombocytopenia; Time Factors | 1973 |
[Symptomatic thrombopenias. Difficulties of early diagnosis and therapeutic possibilities].
Topics: Adult; Blood Platelets; Hemorrhagic Disorders; Hodgkin Disease; Humans; Hydrazines; Immunoelectrophoresis; Lupus Erythematosus, Systemic; Male; Middle Aged; Multiple Myeloma; Prednisone; Purpura; Splenectomy; Thrombocytopenia; Vinblastine; Waldenstrom Macroglobulinemia | 1966 |
Use of a methyl hydrazine derivative (natulan), especially in Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Agents; Child; Female; Hodgkin Disease; Humans; Hydrazines; Leukemia, Lymphoid; Leukopenia; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Thrombocytopenia | 1966 |
Clinical experience with ibenzmethyzin (Natulan) in the treatment of lymphomas and solid tumours.
Topics: Adolescent; Adult; Aged; Amenorrhea; Antineoplastic Agents; Cortisone; Female; Hodgkin Disease; Humans; Hydrazines; Leukopenia; Lymph Node Excision; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Metastasis; Thrombocytopenia | 1967 |
Procarbazine (Natulan) and busulfan in the treatment of polycythemia vera.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Humans; Hydrazines; Leukopenia; Male; Middle Aged; Polycythemia Vera; Thrombocytopenia | 1968 |